 OCALA, Fla., Sept. 20, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today provided a status update on its Phase 2a Human Challenge Trial HCT to test the companys drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus HRV-16, a common cold virus and influenza A virus H3N2. The proposed protocol for the AIM-sponsored study was submitted to the Oxford Research Ethics Committee RECMedicines and Healthcare Regulatory Agency MHRA on September 10, 2021. A meeting is scheduled to review the study on September 24, and the response is expected by mid November. 